Tirzepatide and Fertility: What the Evidence Says and What to Ask Your Doctor

Why the 'not while trying to conceive' recommendation exists

Animal studies raised concerns about developmental effects at doses similar to those used clinically, and because there are no adequate human pregnancy data, UK regulators have taken a precautionary position. Tirzepatide is not recommended for use in pregnancy or breastfeeding, and if a pregnancy is discovered during treatment, the medicine should be stopped and a clinician contacted promptly. The broader GLP-1 class carries the same guidance across the board.

The recommendation to avoid the medicine when trying to conceive is partly precautionary and partly practical: if you become pregnant while on treatment, there will have been foetal exposure before you know about it. Stopping in advance of any attempt to conceive gives you a sensible buffer. How long that buffer should be for you personally (taking into account your health history, your weight-loss progress, and your reproductive goals) is genuinely an individual clinical question, and you can read more about tirzepatide's effects on fertility in its own dedicated page on our site. Our clinical team at nume can discuss the prescribing side of this, but a fertility specialist or your GP holds the broader picture.

One practical step you can take right now, in under a minute: check whether your current contraception method is on the list of non-oral options (a condom, an IUD, an implant or an injection) and note whether a switch might be relevant before you start tirzepatide. That small check could matter if you are currently relying solely on the pill.

The contraception interaction: oral pills and dose increases

Tirzepatide slows gastric emptying. That matters for medicines absorbed in the gut, and the oral contraceptive pill is one of them. UK guidance, reflected on NHS England's weight-management injections page, advises adding a non-oral contraceptive method (a barrier method works) for the first four weeks of starting tirzepatide and for four weeks after every dose increase. If you are currently on the pill and considering this treatment, that is not a reason to avoid it, but it is something to plan for in advance rather than after your first pen arrives. Semaglutide (Wegovy) does not carry the same specific interaction warning, which is a real clinical distinction between the two medicines.

This interaction is manageable. Most people on combined hormonal methods simply add a condom for the relevant windows. If your contraception situation is more complicated (for example, you are using the pill to manage endometriosis or PCOS alongside its contraceptive function) that is worth raising with your GP before starting, because the reproductive-health picture becomes more layered. You can read more about how Mounjaro may affect fertility in men, a separate and less-studied area that we cover in its own right on our site, as well as the related question of how Mounjaro may affect male fertility more broadly.

What weight loss itself may do for fertility

This is where the evidence becomes genuinely hopeful, even though it comes with caveats. Obesity is associated with disrupted sex-hormone levels, reduced ovulatory regularity, and (in people with PCOS) elevated androgens that interfere with conception. Substantial weight loss, however it is achieved, can shift those markers. Menstrual cycles can become more regular. Ovulation can return in people who had stopped ovulating. These are well-documented biological responses, not effects specific to tirzepatide.

The clinical trials for tirzepatide (including SURMOUNT-1, published in the New England Journal of Medicine) enrolled adults with obesity but specifically excluded pregnant women and those planning pregnancy. So while the weight-loss outcomes are substantial (around 20% average reduction at the highest dose over 72 weeks), no fertility endpoints were measured. The inference that weight loss may improve fertility is reasonable and consistent with wider evidence; it is not the same as a demonstrated fertility treatment effect. Anyone making decisions on that basis deserves that distinction spelled out clearly.

If improving fertility is part of your motivation for losing weight, that is a completely valid goal. It is worth telling your prescriber, because it shapes the conversation around when to start, how long to continue, and when to stop if conception becomes the priority. You can read more about how Mounjaro may affect fertility specifically, and about the broader Mounjaro and fertility picture, in related pages on our site.

Having the right conversation before you start

The decision to use tirzepatide when fertility is part of your thinking is not straightforward, and it should not feel like it has to be made alone or in a hurry. There are really two parallel conversations worth having: one with a fertility specialist or your GP about the reproductive-health timeline, and one with a prescriber about the weight-management side. Those conversations can (and often should) happen at the same time.

At nume, a real prescriber reads every consultation the same day. They cannot advise on your fertility treatment plan directly, but they can take into account that conception is on your horizon, flag the contraception interaction, and help you understand the prescribing side of any transition off treatment when the time comes. You can also review our full Mounjaro information page for a thorough overview of the medicine itself, and the weight-loss treatment options available through nume if you are still weighing up which approach fits your situation. If you have questions before starting a consultation, our FAQs cover the most common ones, and the contact page gets you to a member of the team directly. When you are ready, start your free consultation and tell the prescriber where you are in your thinking, that context shapes everything.